Literature DB >> 21191610

Optimized voxel brain morphometry: association between brain volumes and the response to atypical antipsychotics.

Vicente Molina1, Carmen Martín, Alejandro Ballesteros, Alba G Seco de Herrera, Juan Antonio Hernández-Tamames.   

Abstract

To date, few studies have addressed the relationship between brain structure alterations and responses to atypical antipsychotics in schizophrenia. To this end, in this study, magnetic resonance imaging (MRI) and voxel-based morphometry (VBM) were used to assess the relationship between the brain volumes of gray (GM) and white (WM) matters and the clinical response to risperidone or olanzapine in 30 schizophrenia patients. In comparison with healthy controls, the patients in this study showed a bilateral decrease in the anteromedial cerebellar hemispheres, the rectal gyrus and the insula, together with bilateral increases in GM in the basal ganglia. Both patient groups had a significantly smaller volume of WM in a region encompassing the internal and external capsules as compared to the controls. We found an inverse association between striatal size and the degree of clinical improvement, and a direct association between the degree of insular volume deficit and its improvement. The non-responder patient group showed a significant decrease in their left rectal gyrus as compared with the responder group. This study reveals a pattern of structural alterations in schizophrenia associated with the response to risperidone or olanzapine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21191610     DOI: 10.1007/s00406-010-0182-2

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  59 in total

1.  Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia.

Authors:  S Kasper; A Hale; J M Azorin; H J Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1999       Impact factor: 5.270

2.  Subcortical and cortical gray matter differences between Kraepelinian and non-Kraepelinian schizophrenia patients identified using voxel-based morphometry.

Authors:  Vicente Molina; Juan A Hernández; Javier Sanz; Juan C Paniagua; Ana I Hernández; Carmen Martín; Juan Matías; Julia Calama; Berta Bote
Journal:  Psychiatry Res       Date:  2010-09-15       Impact factor: 3.222

Review 3.  The role of the cerebellum in schizophrenia.

Authors:  Nancy C Andreasen; Ronald Pierson
Journal:  Biol Psychiatry       Date:  2008-04-08       Impact factor: 13.382

Review 4.  Psychobiologic correlates of treatment response in schizophrenia.

Authors:  J A Lieberman; J M Alvir; A Koreen; S Geisler; M Chakos; B Sheitman; M Woerner
Journal:  Neuropsychopharmacology       Date:  1996-03       Impact factor: 7.853

5.  Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs.

Authors:  M H Chakos; J A Lieberman; R M Bilder; M Borenstein; G Lerner; B Bogerts; H Wu; B Kinon; M Ashtari
Journal:  Am J Psychiatry       Date:  1994-10       Impact factor: 18.112

6.  Focal gray matter density changes in schizophrenia.

Authors:  H E Hulshoff Pol; H G Schnack; R C Mandl; N E van Haren; H Koning; D L Collins; A C Evans; R S Kahn
Journal:  Arch Gen Psychiatry       Date:  2001-12

7.  Regional volume deviations of brain structure in schizophrenia and psychotic bipolar disorder: computational morphometry study.

Authors:  Colm McDonald; Ed Bullmore; Pak Sham; Xavier Chitnis; John Suckling; James MacCabe; Muriel Walshe; Robin M Murray
Journal:  Br J Psychiatry       Date:  2005-05       Impact factor: 9.319

8.  Follow-up MRI study of the insular cortex in first-episode psychosis and chronic schizophrenia.

Authors:  Tsutomu Takahashi; Stephen J Wood; Bridget Soulsby; Patrick D McGorry; Ryoichiro Tanino; Michio Suzuki; Dennis Velakoulis; Christos Pantelis
Journal:  Schizophr Res       Date:  2009-01-25       Impact factor: 4.939

9.  Voxel-based structural magnetic resonance imaging (MRI) study of patients with early onset schizophrenia.

Authors:  Yujiro Yoshihara; Genichi Sugihara; Hideo Matsumoto; John Suckling; Katsuhiko Nishimura; Takao Toyoda; Haruo Isoda; Kenji J Tsuchiya; Kiyokazu Takebayashi; Katsuaki Suzuki; Harumi Sakahara; Kazuhiko Nakamura; Norio Mori; Nori Takei
Journal:  Ann Gen Psychiatry       Date:  2008-12-22       Impact factor: 3.455

10.  Internal capsule size associated with outcome in first-episode schizophrenia.

Authors:  Thomas Wobrock; Oliver Gruber; Thomas Schneider-Axmann; Wolfgang Wölwer; Wolfgang Gaebel; Mathias Riesbeck; Wolfgang Maier; Joachim Klosterkötter; Frank Schneider; Gerd Buchkremer; Hans-Jürgen Möller; Andrea Schmitt; Stefan Bender; Ralf Schlösser; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-02-17       Impact factor: 5.270

View more
  14 in total

1.  Subcortical modulation in auditory processing and auditory hallucinations.

Authors:  Toshikazu Ikuta; Pamela DeRosse; Miklos Argyelan; Katherine H Karlsgodt; Peter B Kingsley; Philip R Szeszko; Anil K Malhotra
Journal:  Behav Brain Res       Date:  2015-08-11       Impact factor: 3.332

2.  Differential diagnosis of major depression and bipolar disorder.

Authors:  Andrea Schmitt; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-03       Impact factor: 5.270

3.  Longitudinal study of cerebral surface morphology in youth with 22q11.2 deletion syndrome, and association with positive symptoms of psychosis.

Authors:  Petya D Radoeva; Ravi Bansal; Kevin M Antshel; Wanda Fremont; Bradley S Peterson; Wendy R Kates
Journal:  J Child Psychol Psychiatry       Date:  2016-10-27       Impact factor: 8.982

4.  Striatal glutamate, subcortical structure and clinical response to first-line treatment in first-episode psychosis patients.

Authors:  Francisco Reyes-Madrigal; Elisa Guma; Pablo León-Ortiz; Gladys Gómez-Cruz; Ricardo Mora-Durán; Ariel Graff-Guerrero; Lawrence S Kegeles; M Mallar Chakravarty; Camilo de la Fuente-Sandoval
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2021-11-06       Impact factor: 5.067

5.  Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication.

Authors:  Nathan L Hutcheson; David G Clark; Mark S Bolding; David M White; Adrienne C Lahti
Journal:  Psychiatry Res       Date:  2013-10-22       Impact factor: 3.222

6.  Impaired cerebellar-dependent eyeblink conditioning in first-degree relatives of individuals with schizophrenia.

Authors:  Amanda R Bolbecker; Jerillyn S Kent; Isaac T Petersen; Mallory J Klaunig; Jennifer K Forsyth; Josselyn M Howell; Daniel R Westfall; Brian F O'Donnell; William P Hetrick
Journal:  Schizophr Bull       Date:  2013-08-20       Impact factor: 9.306

7.  Structural brain changes associated with antipsychotic treatment in schizophrenia as revealed by voxel-based morphometric MRI: an activation likelihood estimation meta-analysis.

Authors:  Ulysses S Torres; Eduardo Portela-Oliveira; Stefan Borgwardt; Geraldo F Busatto
Journal:  BMC Psychiatry       Date:  2013-12-20       Impact factor: 3.630

8.  Increased timing variability in schizophrenia and bipolar disorder.

Authors:  Amanda R Bolbecker; Daniel R Westfall; Josselyn M Howell; Ryan J Lackner; Christine A Carroll; Brian F O'Donnell; William P Hetrick
Journal:  PLoS One       Date:  2014-05-21       Impact factor: 3.240

9.  Patients with poor response to antipsychotics have a more severe pattern of frontal atrophy: a voxel-based morphometry study of treatment resistance in schizophrenia.

Authors:  Mario Quarantelli; Olga Palladino; Anna Prinster; Vittorio Schiavone; Barbara Carotenuto; Arturo Brunetti; Angela Marsili; Margherita Casiello; Giovanni Muscettola; Marco Salvatore; Andrea de Bartolomeis
Journal:  Biomed Res Int       Date:  2014-07-23       Impact factor: 3.411

Review 10.  Neuroimaging biomarkers to predict treatment response in schizophrenia: the end of 30 years of solitude?

Authors:  Paola Dazzan
Journal:  Dialogues Clin Neurosci       Date:  2014-12       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.